Dashboard
Manage Tickers

BOLTBolt Biotherapeutics, Inc.

Nasdaq boltbio.com


$ 1.12 $ 0.00 (0 %)    

Monday, 22-Apr-2024 14:15:16 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 429.02 $ 0.74 (0.17 %)
DIA $ 385.02 $ 0.01 (0 %)
SPY $ 506.79 $ 0.36 (0.07 %)
TLT $ 88.21 $ -0.21 (-0.24 %)
GLD $ 214.64 $ 0.29 (0.14 %)
$ 1.11
$ 1.12
$ 0.00 x 0
$ 1.13 x 100
$ 1.12 - $ 1.12
$ 0.84 - $ 2.03
50,512
na
41.97M
$ 0.97
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-21-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-07-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-29-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-10-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-30-2022 12-31-2021 10-K
10 11-09-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-31-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
04/03/2024 20:31:20

hc-wainwright--co-maintains-buy-on-bolt-biotherapeutics-maintains-8-price-target
HC Wainwright & Co. Maintains Buy on Bolt ...
03/22/2024 15:00:18

HC Wainwright & Co. analyst Edward White maintains Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $8 price ...

bolt-biotherapeutics-q4-eps-047-beats-048-estimate-sales-209m-beat-171m-estimate
Bolt Biotherapeutics Q4 EPS $(0.47) Beats ...
03/21/2024 20:20:10

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of ...

bolt-biotherapeutics-enrolls-first-patient-in-phase-2-clinical-study-evaluating-bdc-1001-in-patients-with-her2-positive-breast-cancer-previously-treated-with-enhertu
Bolt Biotherapeutics Enrolls First Patient...
12/05/2023 12:02:08

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the t...

bolt-biotherapeutics-q3-eps-043-beats-050-estimate-sales-253m-beat-172m-estimate
Bolt Biotherapeutics Q3 EPS $(0.43) Beats ...
11/09/2023 22:23:19

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of ...

bolt-biotherapeutics-presents-updated-clinical-data-from-phase-1-dose-escalation-trial-of-bdc-1001-as-monotherapy-and-in-combination-with-nivolumab-in-her2-expressing-tumors-at-esmo-2023-congress
Bolt Biotherapeutics Presents Updated Clin...
10/23/2023 14:32:49

Updated safety data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose (RP2D) Improved efficacy with one pa...

bolt-biotherapeutics-announces-first-patient-dosed-in-phase-12-study-of-bdc-3042-in-patients-with-advanced-cancers
Bolt Biotherapeutics Announces First Patie...
10/17/2023 11:04:22

bolt-biotherapeutics-announced-that-updated-clinical-data-from-its-phase-12-dose-escalation-study-of-bdc-1001-will-be-presented-in-a-mini-oral-presentation-at-the-european-society-for-medical-oncology-congress-2023
Bolt Biotherapeutics Announced That Update...
10/16/2023 11:31:53

why-aerwins-technologies-shares-are-trading-higher-by-around-90-here-are-20-stocks-moving-premarket
Why AERWINS Technologies Shares Are Tradin...
10/02/2023 12:11:18

Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares rose 90.2% to $0.2297 in pre-market trading. Aerwins Technologies i...

stocks-that-hit-52-week-lows-on-friday
Stocks That Hit 52-Week Lows On Friday
09/29/2023 18:09:27

  Friday's session saw 112 companies set new 52-week lows.

stocks-that-hit-52-week-lows-on-thursday
Stocks That Hit 52-Week Lows On Thursday
09/28/2023 18:32:08

  During Thursday's session, 406 companies made new 52-week lows.

Core News & Articles
Market-Moving News for September 28th
09/28/2023 12:44:41

BNOX: 700% | Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Po...

the-fda-has-granted-orphan-drug-designation-for-bolt-biotherapeutics-bdc-1001-for-gastric-cancer-including-gastroesophageal-junction-cancer
The FDA Has Granted Orphan Drug Designatio...
09/28/2023 11:04:22

bolt-biotherapeutics-announces-issuance-of-us-patent-covering-dectin-2-targeting-agonist-antibodies-including-bdc-3042
Bolt Biotherapeutics Announces Issuance Of...
09/12/2023 12:07:04

stocks-that-hit-52-week-lows-on-tuesday
Stocks That Hit 52-Week Lows On Tuesday
08/22/2023 17:51:20

  On Tuesday, 210 companies reached new 52-week lows.

hc-wainwright--co-reiterates-buy-on-bolt-biotherapeutics-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Bolt...
08/08/2023 10:11:48

HC Wainwright & Co. analyst Edward White reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $8 price...

bolt-biotherapeutics-q2-eps-048-up-from-061-yoy-sales-143m-up-from-139m-yoy
Bolt Biotherapeutics Q2 EPS $(0.48) Up Fro...
08/07/2023 20:55:16

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.48) per share. This is a 21.31 percent increase over losses...

hc-wainwright--co-reiterates-buy-on-bolt-biotherapeutics-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Bolt...
08/03/2023 17:25:55

HC Wainwright & Co. analyst Edward White reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $8 price...

bolt-biotherapeutics-announced-that-the-first-patients-have-been-dosed-in-phase-2-dose-expansion-trial-of-bdc-1001-for-her2-positive-colorectal-endometrial-and-gastroesophageal-cancers
Bolt Biotherapeutics Announced That The Fi...
08/03/2023 11:42:17

hc-wainwright--co-reiterates-buy-on-bolt-biotherapeutics-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Bolt...
06/05/2023 10:29:47

HC Wainwright & Co. analyst Edward White reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $8 price...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION